ChartRow logo
ELVN
$41.25+6.59%
as of close, Oct 20, 2026
☾ AH $41.25 +6.59%
PeersMRNALLYMDTUNHJNJTMO
Share this page

Enliven Therapeutics Inc. trailing returns

How Enliven Therapeutics Inc. (ELVN) has performed over the last day, week, month and year, over 5 years, and since inception, through October 20, 2026 — price return and dividends side by side, with the worst drop inside each window.

Trailing returns by period#

To 2026-10-20. Price return + dividends = total return. Per year (CAGR) for windows of a year or more, with the cumulative total return beneath. Worst drop: the deepest fall in the price from a high inside the window, and when it bottomed.

PeriodPriceDivsTotalWorst drop
1 day+6.6%+0.0%+6.6%—
5 days+4.5%+0.0%+4.5%-5.5%Oct 16
1 month-16.6%+0.0%-16.6%-24.5%Oct 16
YTD+167.9%+0.0%+167.9%-39.0%Oct 16
1 year+86.5%+0.0%+86.5%-39.0%Oct 2026
5 years+62.6%+0.0%+62.6%+1036.4%-75.6%Apr 2022
Since inception (2020)+16.5%+0.0%+16.5%+175.0%-98.2%Apr 2022

Growth of ELVN#

Actual level with dividends reinvested (solid); dashed lines are each window's constant-rate path from start to today.

  • 5 years+62.6%/year · +1036.4%

Methodology#

Trailing returns measure from the closest close about N years before the latest close (2026-10-20). Cumulative return is the total change over the window; annualized return is the compound annual growth rate (CAGR), shown for windows of a year or more. Price return is the change in ELVN's closing price; total return reinvests dividends (from its split- and dividend-adjusted closes); the dividends column is the difference between the two. The worst drop is the largest fall in the closing price from a high to a later low inside the window, the way a drawdown is usually quoted. See the year-by-year returns for the calendar breakdown. Past performance does not predict future returns; not investment advice.

FAQ#

What is Enliven Therapeutics Inc.'s return since inception?
Since 2020, Enliven Therapeutics Inc. (ELVN) has compounded at about +16.5% a year — +175.0% in total.

More on Enliven Therapeutics Inc.